Interestingly, N-CTD patients shared several features of the MS CSF immune profile, including intrathecal IgG, IgA and IgM synthesis, a BCBD, and increased B and plasma cells compared to Ctrl patients (Fig. 2A, B). The gene discussed is CD40LG; the disease is myeloid sarcoma.